An improved synthesis of 6α-ethylchenodeoxycholic acid (6ECDCA), a potent and selective agonist for the Farnesoid X Receptor (FXR)
- 30 November 2012
- journal article
- Published by Elsevier BV in Steroids
- Vol. 77 (13), 1335-1338
- https://doi.org/10.1016/j.steroids.2012.09.002
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- FXR an emerging therapeutic target for the treatment of atherosclerosisJournal of Cellular and Molecular Medicine, 2010
- Bile Acid Derivatives as Ligands of the Farnesoid X Receptor. Synthesis, Evaluation, and Structure−Activity Relationship of a Series of Body and Side Chain Modified Analogues of Chenodeoxycholic AcidJournal of Medicinal Chemistry, 2004
- The Farnesoid X-receptor Is an Essential Regulator of Cholesterol HomeostasisJournal of Biological Chemistry, 2003
- Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response elementJCI Insight, 2002
- Chemical genomics: Functional analysis of orphan nuclear receptors in the regulation of bile acid metabolismMedicinal Research Reviews, 2001
- Identification of a Chemical Tool for the Orphan Nuclear Receptor FXRJournal of Medicinal Chemistry, 2000
- Identification of a Nuclear Receptor for Bile AcidsScience, 1999
- Bile Acids: Natural Ligands for an Orphan Nuclear ReceptorScience, 1999
- Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BARMolecular Cell, 1999
- Identification of a nuclear receptor that is activated by farnesol metabolitesCell, 1995